If there’s one thing we can count on in life, it’s change, and viruses are no exception. Variants of the original SARS-CoV-2 virus have popped up in different corners of the world and while that might sound a bit scary it’s actually perfectly normal, or even “humdrum” as one Nature study puts it.
While virologists predicted all along that the virus that causes COVID-19 would mutate, what scientists still don’t know exactly is what these variations might mean for how infectious or deadly the virus is. And while we know a handful of COVID-19 variants have circulated throughout the US, pretty much unnoticed by the general public, some variants, particularly the Alpha and Beta variants, which originated in the UK and South Africa, respectively, share some more atypical characteristics that seem to make them more infectious.
Here’s what you need to know about the new mutated versions and COVID-19.
Delta and Kappa: The variants that originated in India (B.1.617)
The variants of most recent concern are the Delta and Kappa variants, both a spin-off of the B.1.617 lineage, which was first identified in India in October 2020, and has since spread to Britain, the US, and recently Israel. It is currently the most common variant in India, which had a massive spike in cases in late April and early May. The lineage that includes Delta and Kappa is known for two major mutations—E484Q and L452R, the first of which may help the virus evade antibodies, according to the New York Times.
The Delta variant in particular has traveled to over 60 countries and triggered a spike in infections in places like the UK. In Singapore, the mutation accounted for 95 percent of variant local COVID samples Bloomberg reports. Additionally, COVID patients in India, where the variant is especially prevalent, are experiencing rarer symptoms from COVID-19 like stomach pain, nausea, vomiting, loss of appetite, hearing loss, and joint pain. Ganesh Manudhane, a Mumbai cardiologist, told Bloomberg he has seen increasing cases of microthrombi, which are clots in small blood vessels, so severe that gangrene develops, and can be life-threatening.
“I saw three to four cases the whole of last year, and now it’s one patient a week,” Manudhane told Bloomberg.
There are also concerns about the current vaccines’ efficacy against the Delta variant. One study showed that two Pfizer doses were 88 percent effective against Delta, compared to 93 percent effective against UK-originated strain, Alpha.
“It is by far the most contagious variant of this virus that we have seen throughout the whole pandemic,” Ashish Jha, dean of the Brown University School of Public Health, told the TODAY show on June 9. “It is what has caused huge spikes in India, and it’s causing a serious increase in cases in the UK despite the fact they’re very vaccinated. So it really is a problem.”
Alpha: The variant that originated in the UK (B.1.1.7)
The COVID-19 variant first detected in the UK—also known as B.1.1.7—was identified on December 14, 2020, causing tightened lockdown rules and border control inside the UK and between other countries. The virus has been found more frequently in southern England, and what has stood out to researchers most is a large number of mutations it’s taken on—a whopping 23 shifts from the original COVID-19 virus that emerged from Wuhan, China in late December 2019.
This variant has spread through the United States, and doubled around every 10 days as of January according to one preprint study.
While scientists believe that the COVID-19 vaccines that are currently being distributed are still effective against this version of the virus and there’s no change in disease severity compared to the original, the B.1.1.7 version is thought to be more contagious. According to the BBC, this variant has the ability to spread between 50 and 70 percent faster than previous forms of the virus, meaning we might have to amp up lockdowns and other techniques to prevent it from spreading.
“The new variant of the virus transmits considerably more effectively than the previous variant and that means control measures that have worked in the past to contain spread may not work in the future,” said Neil Ferguson, a professor of epidemiology at Imperial College London, in a release.
No one knows for sure what makes this variant more contagious. Some surmise that it might have certain traits that allow the virus to enter human cells more easily. Some preliminary studies also suggest that people with the variant may have more copies of the virus circulating in their ears, nose, and throat compared to those infected with the original or other variants.
As of mid-February of 2021, the B.1.1.7 variant has been detected in over 70 countries and 33 states.
Beta: The variant that originated in South Africa (B.1.351)
A few days after the discovery of the UK-originated, Alpha variant, another variant—known as B.1.351—popped up in South Africa that displays some similar mutations. Research has found that this variant also is becoming more dominant than earlier variants throughout the country, nearly replacing the other versions in the Eastern Cape, Western Cape, and KwaZulu-Natal provinces.
Similar to Alpha, the Beta variant doesn’t necessarily mean people get more sick, but it certainly appears to be more transmissible. In fact, a recent study shows that the Beta variant has no evidence of triggering strange clinical symptoms.
“We are not helpless in the face of this variant,” Richard Lessells, a clinical researcher at the Africa Centre for Health and Population Studies told the Associated Press. “We can change our behavior to give the virus less opportunities to spread.”
Unlike Alpha, some scientists are worried that B.1.351, or Beta, may be more resistant to the current vaccines in place due to extensive alterations to the spike proteins. Current mRNA COVID-19 vaccines use these spike proteins as a tool to teach our bodies to recognize, and fight, the virus.
Research over the past several months has been done to test out the efficacy of the vaccine against this variant. Back in January, according to Reuters, scientists at BioNTech, the German biotechnology company that partnered with Pfizer to develop one of the vaccines currently in use, said they were testing the vaccines against the new variants and, if needed, could make tweaks in as little as six weeks. It’s still unclear if tweaks to the available vaccines are needed at all, however.
As of June 2021, less than one percent of the South African population has been vaccinated. President Cyril Ramaphosa said back in December that an estimated 10 percent of South Africa’s population of 60 million will receive the vaccine in the first months of 2021, according to the AP.
Gamma: The variant that originated in Brazil (P.1 lineage)
The Gamma lineage was spotted in four people in Japan after a trip to Brazil. It developed late last year in Brazil’s Amazon region, becoming dominant there, and in surrounding South American cities. As of January 2021, the variant has also been found in parts of Europe, as well as in Oklahoma and Minnesota in the United States. Most recent reports place the variant in at least 37 countries. Like the Beta variant, studies have shown that there aren’t any strange side effects of this particular mutation.
A close cousin to the Beta variant, the Gamma variant has similar mutations, including what virologists have dubbed the E484K mutation, which affects the spike protein and may make it trickier for certain vaccines to provide maximum effectiveness. Another major worry, reports NPR, is that of reinfection rates. The number of mutations on P.1 variants can theoretically help the virus evade antibody response, which may be why Manaus, Brazil is seeing a resurgence of this particular strain, despite already having a huge outbreak a year ago.
“If you were to ask me right now, what’s most concerning of all the things that I’ve heard so far, it’s the fact that they are reporting a sudden increase in cases in Manaus, Brazil,” University of Massachusetts virus expert Jeremy Luban told NPR. “Manaus already had 75 percent of people infected [in the spring of last year].”
Eta: Another variant that originated in the UK (B.1.525)
A report released on February 15 by researchers at the University of Edinburgh in Scotland has detailed another UK-based variant dating back to December. As of February, the variant has been spotted in 11 different countries, including Canada, Denmark, the US, Ghana, and Australia. Similar to the Alpha and Beta variants, this variant includes the E484K mutation on the spike protein, which again can influence how well the vaccines work against it.
“We don’t yet know how well this [new] variant will spread, but if it is successful it can be presumed that immunity from any vaccine or previous infection will be blunted,” Simon Clarke, an associate professor of cellular microbiology at the University of Reading, told the Guardian.
Epsilon: The variant that originated in Northern California (B.1.427, B.1.429)
In January, virologists began investigating a variant that has now become the predominant strain in California. The mutation—known as L452R—isn’t entirely new. Researchers first identified it in Denmark back in March of 2020, and it quickly spread to other countries, including the United States. However cases linked to the variant have spiked in Northern California. Researchers there identified it in 25 percent of samples found between mid-December and early January, a leap from less than four percent in the previous three weeks, according to The Washington Post.
Multiple large outbreaks in January in Santa Clara County, located just south of San Francisco, have included this variant, according to a release by the county. Recent research has found that this particular variant is 40 percent more effective at infecting human cells than other variants and can potentially evade our immune systems, according to The New York Times. The recent research was based on work that has not yet been peer-reviewed and will be published online as a “pre-print” shortly.
“This variant carries three mutations, including L452R, in the spike protein, which the virus uses to attach to and enter cells, and is the target of the two vaccines that are currently available in the United States,” Charles Chiu, a virologist and professor of laboratory medicine at UCSF, said in the release. “Now that we know this variant is on the rise in our local communities, we are prioritizing it for study. Researchers at UCSF and elsewhere will now be able to perform the critical laboratory experiments to determine whether or not this virus is more infectious or affects vaccine performance.”
Still, there is some doubt that B.1.427/B.1.429 is as dangerous as the UK-based variant, B.1.117, which arrived in California in December.